Christopher U. Missling, PhD is President and CEO of Anavex Life Sciences Corp, has over 20 years of healthcare industry experience within large pharmaceutical companies and the biotech industry. Prior to joining Anavex, he served as the Chief Financial Officer of Curis and ImmunoGen and previously at Aventis (now Sanofi). Christopher’s work is dedicated to finding potential cures for rare diseases especially for neurodevelopmental diseases, like Rett syndrome, as well as neurodegenerative diseases, like Parkinson’s disease and Alzheimer’s disease. Dr. Missling is working with his team to advance new potential treatments through clinical trials by involving also genomic analysis. Dr. Missling has an MS and PhD from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management and WHU Otto Beisheim School of Management.